(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.27%) $78.69
(0.14%) $2.20
(0.07%) $2 332.90
(0.26%) $27.69
(0.17%) $966.90
(-0.02%) $0.929
(-0.35%) $10.84
(-0.13%) $0.796
(-0.11%) $91.35
Quarter results today
(bmo 2024-05-06)
Expected move: +/- 2.10%
-0.88% INR 6 293.45
Live Chart Being Loaded With Signals
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments...
Stats | |
---|---|
Объем за сегодня | 452 710 |
Средний объем | 365 711 |
Рыночная капитализация | 1 047.64B |
EPS | INR0 ( 2024-01-29 ) |
Дата следующего отчета о доходах | ( INR0 ) 2024-07-26 |
Last Dividend | INR40.00 ( 2023-07-11 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 20.10 |
ATR14 | INR6.92 (0.11%) |
Объем Корреляция
Dr. Reddy's Laboratories Корреляция
10 Самые положительные корреляции | |
---|---|
SETF10GILT.NS | 0.933 |
ASHIANA.NS | 0.919 |
MOGSEC.NS | 0.915 |
ADORWELD.NS | 0.905 |
BHARATWIRE.NS | 0.903 |
IZMO.NS | 0.898 |
BAJAJ-AUTO.NS | 0.893 |
GTNTEX.NS | 0.884 |
CYIENT.NS | 0.883 |
MASPTOP50.NS | 0.882 |
10 Самые отрицательные корреляции | |
---|---|
STARTECK.NS | -0.898 |
SUNCLAYLTD.NS | -0.875 |
SCI.NS | -0.87 |
TEAMLEASE.NS | -0.856 |
ORTINLAB.NS | -0.853 |
MOHOTAIND.NS | -0.851 |
EASTSILK.NS | -0.851 |
ROLTA.NS | -0.844 |
CLNINDIA.NS | -0.844 |
GENESYS.NS | -0.839 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Dr. Reddy's Laboratories Корреляция - Валюта/Сырье
Dr. Reddy's Laboratories Финансовые показатели
Annual | 2022 |
Выручка: | INR245.88B |
Валовая прибыль: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Выручка: | INR245.88B |
Валовая прибыль: | INR169.30B (68.86 %) |
EPS: | INR271.43 |
FY | 2022 |
Выручка: | INR214.39B |
Валовая прибыль: | INR113.84B (53.10 %) |
EPS: | INR142.08 |
FY | 2021 |
Выручка: | INR189.72B |
Валовая прибыль: | INR103.08B (54.33 %) |
EPS: | INR103.94 |
Financial Reports:
No articles found.
Dr. Reddy's Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR60.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR40.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR2.50 | 2003-08-08 |
Last Dividend | INR40.00 | 2023-07-11 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | INR363.00 | -- |
Avg. Dividend % Per Year | 0.62% | -- |
Score | 3.63 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.28 | |
Div. Directional Score | 8.85 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR40.00 | 1.93% |
2019 | INR20.00 | 0.77% |
2020 | INR25.00 | 0.87% |
2021 | INR25.00 | 0.48% |
2022 | INR60.00 | 1.24% |
2023 | INR40.00 | 0.94% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SESHAPAPER.NS | Dividend Knight | 2023-06-07 | Annually | 23 | 1.14% | |
MANAKCOAT.NS | Dividend Junior | 2023-08-22 | Sporadic | 4 | 0.09% | |
GOODYEAR.NS | Dividend Knight | 2023-07-26 | Annually | 5 | 4.02% | |
AVANTIFEED.NS | Dividend Junior | 2023-08-03 | Annually | 14 | 0.86% | |
TRIL.NS | Dividend Junior | 2023-07-27 | Sporadic | 17 | 0.22% | |
PILANIINVS.NS | Dividend Junior | 2023-08-29 | Annually | 13 | 0.56% | |
JKCEMENT.NS | Dividend Junior | 2023-08-01 | Annually | 19 | 0.37% | |
DEVIT.NS | Dividend Junior | 2023-09-22 | Annually | 8 | 0.28% | |
SMSPHARMA.NS | Ex Dividend Junior | 2023-09-22 | Annually | 18 | 0.12% | |
MINDTECK.NS | Dividend Junior | 2023-08-04 | Sporadic | 8 | 0.28% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.192 | 1.500 | 6.15 | 9.23 | [0 - 0.5] |
returnOnAssetsTTM | 0.140 | 1.200 | 5.33 | 6.40 | [0 - 0.3] |
returnOnEquityTTM | 0.209 | 1.500 | 8.79 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.127 | -1.000 | 8.73 | -8.73 | [0 - 1] |
currentRatioTTM | 2.55 | 0.800 | 2.26 | 1.809 | [1 - 3] |
quickRatioTTM | 1.800 | 0.800 | 4.12 | 3.30 | [0.8 - 2.5] |
cashRatioTTM | 0.0784 | 1.500 | -0.675 | -1.013 | [0.2 - 2] |
debtRatioTTM | 0.0532 | -1.500 | 9.11 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 44.26 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0741 | -1.500 | 9.70 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.641 | 1.000 | 2.66 | 2.66 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.240 | 1.000 | 7.20 | 7.20 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.70 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.728 | 0.800 | 8.48 | 6.79 | [0.5 - 2] |
Total Score | 11.41 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.11 | 1.000 | 8.07 | 0 | [1 - 100] |
returnOnEquityTTM | 0.209 | 2.50 | 9.22 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 172.31 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.634 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.84 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.127 | 1.500 | 8.73 | -8.73 | [0 - 1] |
pegRatioTTM | 0.221 | 1.500 | -1.861 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.198 | 1.000 | 7.56 | 0 | [0.1 - 0.5] |
Total Score | 6.28 |
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа